Article Text

Download PDFPDF
Subannular repair for secondary mitral regurgitation: a step towards peaceful conversations
  1. Sorin V Pislaru1,
  2. Vuyisile T Nkomo2
  1. 1 Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
  2. 2 Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
  1. Correspondence to Dr Sorin V Pislaru, Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA; pislaru.sorin{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Asking “what do you think about functional mitral regurgitation (MR)?” is a sure way to start a heated debate at any hypothetical joint cardiology—cardiac surgery dinner. Indeed, other than secondary MR is a distinct entity from primary disease and that medical therapy is the first line of treatment, there seems to be unanimous disagreement on everything else—from quantitation (echo vs MRI, proximal isovelocity surface area (PISA) vs other methods, what should be considered severe regurgitation) to the best interventional strategy (percutaneous vs surgical, repair vs replacement). Pausch et al provide new evidence for the role of cardiac surgery with their short-term (1 year) results of relocating both papillary muscles (subannular mitral valve repair) in combination with annuloplasty from the reform-MR prospective multicentre registry.1 This group of highly experienced mitral valve surgeons performed the combined intervention at five sites in Germany. The initial results in 94 patients seem very promising, with a 1.1% in-hospital mortality and a 4.2% rate of recurrent ≥MR at 1 year. The authors must be commended for creating the prospective registry and for their superb surgical skills. Indeed, perioperative mortality was well below the 4.8% predicted by EuroSCORE II and 3.1% by the Society of Thoracic Surgeons. However, a number of unanswered questions were openly discussed by the authors and must be addressed before declaring this surgical technique the optimal approach in patients with ventricular secondary MR.

What is the role of surgery in comparison with medical therapy?

As functional MR is a disease of the cardiac chambers rather than of the valve, interventional therapy must come …

View Full Text


  • Twitter @SorinVPislaru

  • Contributors The authors have contributed equally to the editorial.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Linked Articles